Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Deals

Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development

Fineline Cube Aug 29, 2024

CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100...

Company Medical Device

Advancing Peripheral Artery Disease Care: Boston Scientific’s JETSTREAM Receives Marketing Nod in China

Fineline Cube Aug 29, 2024

NEW YORK—Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical solutions, has secured a...

Policy / Regulatory

China’s New Medical Device Regulations: A Comprehensive Framework for Industry Growth and Safety

Fineline Cube Aug 29, 2024

BEIJING—China’s National Medical Products Administration (NMPA) has unveiled a draft proposal for the “Medical Device...

Company

Innovent Biologics Reports 46.3% YOY Revenue Growth and Expands Portfolio with New Approvals and NDAs

Fineline Cube Aug 29, 2024

Innovent Biologics, Inc., a leading biopharmaceutical company based in China and listed on the Hong...

Company Deals

Tigermed Partners with Beijing Government to Open North Headquarters, Expanding Collaboration in Biotech

Fineline Cube Aug 29, 2024

Tigermed, a prominent Contract Research Organization (CRO) with a presence in both Shenzhen (SHE: 300347)...

Company

Luye Pharma Group’s 2024H1 Revenue and Net Profits Surge, Driven by Oncology and CNS Therapy Revenues

Fineline Cube Aug 29, 2024

Luye Pharma Group, a China-based pharmaceutical company listed in Hong Kong (HKG: 2186), has reported...

Company

Asieris Pharmaceuticals Reports Explosive 103,397.96% YOY Revenue Growth in 2024H1 Financial Report

Fineline Cube Aug 29, 2024

Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176),...

Company

Online Pharmacy Service Drives Jianke.com’s Revenue Growth in H1 2024 Amid Diverse Business Segments

Fineline Cube Aug 29, 2024

Jianke.com, a China-based smart healthcare service platform, has unveiled its financial report for the first...

Company Drug

Jiangxi Jemincare Secures First Generic Approval for GSK’s Requip in China

Fineline Cube Aug 28, 2024

Jiangxi Jemincare Group, based in China, has received marketing approval from the National Medical Products...

Company

AstraZeneca to Invest $135 Million in Swedish Biomanufacturing Facility Expansion

Fineline Cube Aug 28, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN) , the UK-based biopharmaceutical leader, has announced a plan to...

Company Deals

Peijia Medical Secures Exclusive Rights to NowYon’s YonFlow Device in Greater China

Fineline Cube Aug 28, 2024

Peijia Medical Ltd (HKG: 9996) has entered into a licensing agreement with NowYon Medical, securing...

Company Drug

Sanofi Halts Flu Vaccine Distribution in China Amid Potency Concerns

Fineline Cube Aug 28, 2024

Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has reportedly suspended the distribution and sale of...

Company Deals

Frontier Biotechnologies to Sell 70% of API Unit to Duo Rui Pharma for RMB 10 Million

Fineline Cube Aug 28, 2024

Nanjing-based Frontier Biotechnologies Inc. is poised to divest a 70% stake in its peptide active...

Company

Johnson & Johnson China’s Cardiovascular and Professional Solutions Division Head, Kevin Chen, Resigns for New Opportunities

Fineline Cube Aug 28, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading US multinational conglomerate, has announced the resignation...

Company

Everest Medicines Reports 158% Revenue Growth in 2024 H1, Driven by Pharmaceutical Sales and Operational Efficiency

Fineline Cube Aug 28, 2024

Everest Medicines, a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1952),...

Company Drug

JW Therapeutics’ CAR-T Therapy Carteyva Secures NMPA Approval for Mantle Cell Lymphoma Indication

Fineline Cube Aug 28, 2024

JW Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Drug

Shanghai-Based ANEXT Commences Clinical Trials for Exosome Product ANEXT FIT CELL in Respiratory Conditions

Fineline Cube Aug 28, 2024

ANEXT, a Shanghai-based exosome specialist, has launched two clinical studies for their product ANEXT FIT...

Company

Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report

Fineline Cube Aug 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...

Company Deals

Shanghai BDgene Partners with SPH RD to Develop Hemophilia Treatments Using BDlendi Insulator Technology

Fineline Cube Aug 28, 2024

Shanghai BDgene Technology Co., Ltd, a leading gene therapy specialist based in China, has entered...

Company Drug

Legend Biotech’s Carvykti Receives NMPA Approval for Relapsed/Refractory Multiple Myeloma After Multi-Center Phase II Study

Fineline Cube Aug 28, 2024

Legend Biotech Corporation (NASDAQ: LEGN) has secured a significant milestone with the announcement of marketing...

Posts pagination

1 … 298 299 300 … 658

Recent updates

  • Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
  • WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.